Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation

@inproceedings{Fisher2012ObservationAA,
  title={Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation},
  author={Rosalie Anne Fisher and Alexandra M C Pender and Kiruthikah Thillai and Simon Chowdhury and Lisa M. Pickering and Komel Khabra and Martin Gore and James Larkin},
  booktitle={Front. Oncol.},
  year={2012}
}
1 Clinical Research Fellow, Department of Medical Oncology, The Royal Marsden Hospital, London, UK 2 Specialist Registrar, Department of Medical Oncology, The Royal Marsden Hospital, London, UK 3 Clinical Research Fellow, Department of Medical Oncology, Guy’s and St. Thomas’ Hospital, London, UK 4 Consultant Medical Oncologist, Department of Medical Oncology, Guy’s and St. Thomas’ Hospital, London, UK 5 Consultant Medical Oncologist, Department of Medical Oncology, The Royal Marsden Hospital… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-9 of 9 references

This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction

Fisher, Pender, +5 authors Larkin
2012

An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage

K. M. Ardeshna, W. Qian, +4 authors E C.F.
2010
View 2 Excerpts

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…